FDA To Investors: Ask For The Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Top new drug review officials feel biopharma investors' pain when it comes to interpreting "complete response" actions.
You may also be interested in...
FDA Gets Investor Advice On Transparency At White House Gathering
FDA recently met with venture capitalists and drug industry leaders to discuss the agency's initiative to become more transparent. While such get-togethers are not unusual, the location of this one signaled how significant the topic is to FDA. Rather than meet at the agency's still-being-renovated headquarters in White Oak, participants gathered at the White House
FDA Gets Investor Advice On Transparency At White House Gathering
FDA recently met with venture capitalists and drug industry leaders to discuss the agency's initiative to become more transparent. While such get-togethers are not unusual, the location of this one signaled how significant the topic is to FDA. Rather than meet at the agency's still-being-renovated headquarters in White Oak, participants gathered at the White House
J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.